Background: Taxane treatment may be a suitable therapeutic option for patients with
Conclusions: Cabazitaxel efficiently inhibits prostate cancer growth despite the high expression of constitutively active AR-V7. Acquired cabazitaxel resistance involving overexpression of efflux transporter ABCB1 can be reverted by bicalutamide or enzalutamide treatment, indicating the great clinical potential for combined treatment with cabazitaxel and anti-androgens.
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| INTRODUCTION
Prostate cancer is one of the most commonly diagnosed malignancies and a leading cause of cancer mortality amongst men living in developed countries. 1 Advanced prostate cancer is treated with androgen deprivation therapy, which is initially efficient in most cases, but eventually gives disease progress into a lethal stage known as castration-resistant prostate cancer (CRPC). The suggested underlying mechanisms behind CRPC include androgen receptor (AR) amplifications, AR mutations, constitutively active AR variants, intracrine steroid synthesis, and AR bypassing mechanisms. 2 For many years, docetaxel was the only available treatment for CRPC, but now several novel therapies with different mechanisms of action are approved 3 ; abiraterone, a steroidogenesis inhibitor blocking the CYP17A1 enzyme, the novel AR antagonist enzalutamide, the radioisotope radium-223, the immunotherapy Sipuleucel-T, and a new tubulin-blocking taxane, cabazitaxel. [4] [5] [6] [7] [8] In a previous study, we identified a sub-group of patients with CRPC with bone metastases expressing high levels of the constitutively active AR variant 7 (AR-V7) having a very poor prognosis. 9 Further research has shown that AR-V7 messenger RNA (mRNA) detection in circulating tumor cells or in peripheral blood of patients with CRPC indicates a likely resistance to treatment with enzalutamide and abiraterone, but not to taxanes, suggesting that cabazitaxel might be a suitable treatment for patients with high tumor expression of AR variants. [10] [11] [12] [13] [14] [15] Therefore, the aim of this study was to investigate the effects of cabazitaxel on human 22Rv1 prostate cancer xenografts, expressing high levels of constitutively active AR-V7 along with other AR variants (AR-V1-6, V9, V12-14), [16] [17] [18] [19] in comparison to effects of surgical castration and abiraterone treatment. We also wanted to explore mechanisms behind acquired cabazitaxel resistance. For this purpose, cabazitaxel resistant cell lines were established.
| MATERIALS AND METHODS

| Cell culture
The 22Rv1 cell line (American Type Culture Collection [ATCC], CRL-2505) was maintained according to ATCC instructions in RPMI 1640 + GlutaMAX supplemented with 10% fetal bovine serum (FBS), 100 U penicillin/mL and 100 µg streptomycin/mL, 10 mM HEPES and 1 mM sodium pyruvate (Thermo Fisher Scientific). Cabazitaxel resistant cell lines (below) were maintained in RPMI with 10% charcoal-stripped FBS (Thermo Fisher Scientific). , mice were randomized and selected for treatment with castration by surgical incision (n = 7), abiraterone (n = 9), cabazitaxel (n = 6), castration plus abiraterone (n = 8), or castration plus cabazitaxel (n = 11) of which six animals received repeated cabazitaxel treatment at tumor regrowth.
| Treatment of 22Rv1 xenografts
Control animals received sham operation (n = 5), vehicle for abiraterone (n = 5) or cabazitaxel (n = 5), or sham operation plus vehicle for abiraterone (n = 2) or cabazitaxel (n = 6). Abiraterone acetate (kindly provided by Janssen Cilag AB) was diluted to 40 mg/mL in 5% benzyl alcohol, 95% safflower oil and given daily by intraperitoneal injections of 0.5 mmol/kg. Cabazitaxel was received as frozen aliquots of Jevtana 
| Evaluation of cabazitaxel resistance
Resistance to cabazitaxel was tested in vitro by growing triplicates of 
| Simvastatin sensitivity
Simvastatin was purchased from Sigma-Aldrich and activated according to the protocol from the vendor. Resistance to simvastatin was tested in vitro by growing quadruplicates of 1 × 10 4 cells in 96-well plates for 4 days in media containing 0 to 100 µmol/L simvastatin. Cell viability was then assayed using CellTiter Glo as described above.
| Androgen receptor activity
The Cignal Lenti Reporter assay (Qiagen) was used to determine the AR activity of the cells, according to the protocol from the vendor. 
| RNA and protein extraction
Total RNA and protein were extracted using the AllPrep DNA/RNA/ Protein Mini Kit (QIAGEN), according to manufacturerʼs protocol and with protein fractions dissolved in 5% sodium dodecyl sulfate. RNA and protein concentrations were determined by absorbance measurements and RNA quality was verified with the 2100 Bioanalyzer (Agilent Technologies) as RNA integrity number ≥8.
| Gene expression analysis
Gene expression profiles were obtained by human HT12 v4.0 Illumina
Beadchip analysis, according to manufacturersʼ description (Illumina).
Data analysis was performed with the GenomeStudio software (version 2011.1, Illumina). Samples were normalized using the average algorithm.
Gene probes with average signals above two-time the mean background level in at least one sample were included, leaving 14 728 probes for further analysis. Differentially expressed genes were identified by the t test (P < .05). Genes defined to have a fold-change ≥2 were subjected to multivariate modeling and to functional pathway analysis.
| Multivariate modeling
Unsupervised principal component analysis (PCA) was used to create an overview of the variation in the transcription data and to detect clusters and trends among samples and expressed genes. Data were mean-centered before analysis, and models were validated by sevenfold cross-validation. Multivariate statistical analysis was performed in SIMCA version 15.0.2 (Umetrics, Umeå, Sweden).
| Functional pathway analysis
Gene set enrichment analysis was performed by the MetaCore software (GeneGo, Thomson Reuters, New York, NY). Sets of genes associated with a functional process (pathway map) were determined as significantly enriched based on P values representing the probability for a process to arise by chance, considering the numbers of enriched gene products in the data versus the number of genes in the process. P values were adjusted by taking into account the rank of the process, given the total number of processes in the MetaCore ontology.
| Western blotting
Protein extracts from replicate samples were pooled in equal amounts and 10 to 50 µg protein per sample was separated by 4%
to 20% Mini-PROTEAN TGX stain-free protein gels (Bio-Rad Laboratories) and transferred onto a nitrocellulose membrane using the Trans-Blot Turbo transfer system (Bio-Rad Laboratories). 
| Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated through graded ethanol. Endogenous peroxidase activity was blocked with 3% H 2 O 2 in methanol followed by antigen retrieval using Tris-EDTA (pH 9) and blocking with Dako Figure 1D ).
| Establishment of cabazitaxel resistant cell lines
To study mechanisms behind cabazitaxel resistance, cells from three were grown in charcoal-stripped media and mice were castrated. As seen in Figure 2B ,C and Figure S1B , there was a clear difference in cabazitaxel response/resistance manifested as rapid growth of the 22Rv1-CabR1 and 22Rv1-CabR2 xenografts during cabazitaxel treatment, while the control 22Rv1 xenografts clearly regressed.
| Mechanisms behind cabazitaxel resistance
To identify mechanisms behind cabazitaxel resistance, total RNA from 22Rv1-CabR1, 22Rv1-CabR2, and parental 22Rv1 cells cultured in charcoal-stripped media was analyzed in triplicates by The cabazitaxel resistant cell lines also showed induction of prostate associated transcripts (NKX3-1, STEAP1, STEAP2, and SLC45A3) ( Table 1) . As this might reflect a general increased in AR activity in 22Rv1-CabR1 and 22Rv1-CabR2 compared with parental 22Rv1 cells, the general AR activity in the cell lines were examined using an AR reporter assay in the absence and presence of DHT.
Surprisingly, the resistant cell lines showed lower endogenous AR activity than the parental 22Rv1 cells and also less induction by DHT stimulation ( Figure 3C ). A similar tendency was seen for PSA secretion; with 22Rv1 producing the highest and 22Rv1-CabR1 the lowest PSA amount per cell ( Figure 3D ). In line with this, the 22Rv1-CabR1 cell line showed lower AR levels than the other cell lines ( Figure 3E and Figure 4) . Notably, the AR-V levels did not obviously differ in relation to cabazitaxel resistance.
Pathway analysis of differentially expressed genes in the cabazitaxel resistant cell lines (Table S1 ) indicated a strong upregulation of the SCAP/SREBP transcriptional control of cholesterol and fatty acid biosynthesis in 22Rv1-CabR2, but not in 22Rv1-CabR1 cells (Table S2 ).
| Anti-androgens partly restores susceptibility to cabazitaxel
To confirm that the cabazitaxel resistance in 22Rv1-CabR1 and 22Rv1-CabR2 was caused by increased ABCB1 expression, cells were T A B L E 1 Genes with significantly increased expression levels (P < .05, FC > 2) in both cabazitaxel resistant cell lines; 22Rv1-CabR1 and 22Rv1-CabR2, in comparison to control 22Rv1 cell line gene codes for the ABCB1 protein that is also known as the multidrug resistance protein 1 or the P-glycoprotein with known function as a drug efflux pump. 24 The ABCB1 protein has been shown to mediate acquired docetaxel-resistance in several prostate cancer models. 20, 25, 26 Cabazitaxel shows less ABCB1 affinity than docetaxel and was initially chosen for clinical development based on its activity in the taxane-resistant model system. 27, 28 Still, ABCB1 has been shown to mediate cross-resistance to cabazitaxel in docetaxel- 
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In conclusion, this study shows initially pronounced response to cabazitaxel in the prostate cancer 22Rv1 xenograft model expressing constitutively active, LBD-truncated AR variants (including AR-V7).
Sub-sequential development of cabazitaxel resistance was associated with induced expression of the ABCB1 drug efflux transporter as well as by increased cholesterol biosynthesis. Resistance could be reversed by the ABCB1 inhibitor elacridar and partly overcome by coadministration of the AR-antagonists bicalutamide and enzalutamide. Taken together, our results show great translational potential suggesting that combined treatment with taxanes and antiandrogens could be used to overcome and/or delay acquired cabazitaxel resistance in patients with prostate cancer.
